AbbVie Inc

9 oct. 2026, 23:00 UTC

AbbVie Inc. is experiencing a notable decline in after-hours trading, reaching its lowest point since Friday's close, reversing a trend of higher closes.

8 oct. 2026, 23:05 UTC

AbbVie Inc shares are slightly lower in after-market trading, dipping just below Thursday's close after reaching an early peak.

7 oct. 2026, 23:05 UTC

AbbVie Inc received FDA Breakthrough Therapy Designations for telisotuzumab adizutecan, with the stock modestly higher in after-market trading amid strong investor interest.

6 oct. 2026, 23:15 UTC

AbbVie Inc's shares are trading modestly lower in after-market hours, continuing a recent trend of fluctuations within a narrow range.

5 oct. 2026, 23:00 UTC

AbbVie Inc. updated its Q3 adjusted diluted EPS guidance to $3.73-$3.77, while revising 2026 full-year guidance down to $13.76-$13.96; shares were roughly flat in after-market trading.

2 oct. 2026, 23:05 UTC

AbbVie Inc has seen a slight increase in after-market trading, continuing its advance since Friday's close and fluctuating near the upper end of its one-month trading range.

1 oct. 2026, 23:15 UTC

AbbVie Inc is experiencing routine after-market trading, advancing slightly since Thursday's close, despite retracing to near the low end of today's range.

30 sept. 2026, 23:00 UTC

AbbVie shares are trading modestly higher in after-market hours following the announcement of a late-breaker presentation at the 2026 European Academy of Dermatology Congress.

29 sept. 2026, 23:45 UTC

AbbVie Inc is seeing a slight increase in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

28 sept. 2026, 23:30 UTC

AbbVie Inc's stock is trading higher in after-market hours following FDA approval of JUVMO™ tablets, the first selective D1/D5 receptor agonist for Parkinson's disease.

25 sept. 2026, 23:51 UTC

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

24 sept. 2026, 20:07 UTC

AbbVie Inc. shares fell slightly despite receiving Health Canada approval for EPKINLY in combination with lenalidomide and rituximab for treating follicular lymphoma.

23 sept. 2026, 23:01 UTC

AbbVie Inc. is down slightly in after-market trading, pulling back from an earlier session high, with a "Sell" rating and a price target of $191.

22 sept. 2026, 20:07 UTC

AbbVie received European Commission approval for RINVOQ to treat active polyarticular juvenile idiopathic arthritis, leading to a modest increase in shares.

21 sept. 2026, 20:06 UTC

AbbVie Inc. is collaborating with Iambic Therapeutics on small molecule therapies, while also acquiring a stake in ADARx Pharmaceuticals, driving shares higher.

18 sept. 2026, 23:06 UTC

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

16 sept. 2026, 19:26 UTC

AbbVie shares moved lower as traders monitor the stock's approach to a 52-week high, with $267.47 seen as a critical resistance level.

15 sept. 2026, 23:01 UTC

AbbVie Inc. shares fell in after-hours trading, reflecting broader market negativity following a decline in the New York Empire State Manufacturing Index.

14 sept. 2026, 21:56 UTC

Shares of AbbVie Inc. are trading higher in after-market hours, maintaining a position above the 20-day moving average and reflecting recent upward trends.

11 sept. 2026, 20:08 UTC

AbbVie Inc. shares are higher following positive Phase 3 LUNA study results for atogepant and strong response rates for investigational BCMA×CD3 BiTE in multiple myeloma trials.

10 sept. 2026, 23:41 UTC

AbbVie Inc declared a quarterly dividend of $1.73, with a record date of October 15, 2026. Shares are higher in after-hours trading.

9 sept. 2026, 23:01 UTC

AbbVie Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market dynamics and rising inflation concerns linked to geopolitical tensions.

8 sept. 2026, 23:06 UTC

AbbVie Inc. shares are higher in after-market hours, following a pullback earlier in the session amid broader market expectations for a Federal Reserve rate hike.

4 sept. 2026, 23:05 UTC

AbbVie Inc. shares are lower in after-market hours, reflecting cautious market sentiment amid mixed economic signals and a slight uptick in the unemployment rate.

3 sept. 2026, 23:11 UTC

AbbVie Inc. shares are trading higher in after-market hours following positive results from the Phase 3 CERVINO study of etentamig for multiple myeloma.

2 sept. 2026, 23:51 UTC

AbbVie Inc. shares are lower in after-market trading, despite remaining above the 20-day moving average, amid a weaker-than-expected ADP payrolls report.

1 sept. 2026, 23:56 UTC

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

31 août 2026, 23:01 UTC

AbbVie Inc shares are higher in after-market trading, reflecting positive momentum. No specific company news was identified to explain the price movement.

28 août 2026, 20:08 UTC

AbbVie shares are lower as the company seeks European approval for SKYRIZI. Rising U.S. Treasury yields amid inflation concerns contribute to market declines.

27 août 2026, 23:01 UTC

AbbVie Inc. seeks European approval for SKYRIZI to treat Crohn's disease. Shares are higher in after-hours trading following a recent dip.